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Abstract
Background: Mesenchymal stem cells (MSCs) have prospective applications in regenerative medicine and tissue
engineering but to what extent phenotype and differentiation capacity alter with ageing is uncertain.
Consequently, any loss in functionality with age would have profound consequences for the maintenance of tissue
viability and the quality of tissues. Proteomics enables the set of proteins responsible for a particular cell phenotype
to be identified, as well as enabling insights into mechanisms responsible for age-related alterations in
musculoskeletal tissues. Few proteomic studies have been undertaken regarding age-related effects on tissue
engineered into cartilage and bone, and none for tendon. This study provides a proteome inventory for
chondrogenic, osteogenic and tenogenic constructs synthesised from human MSCs, and elucidates proteomic
alterations as a consequence of donor age.
Methods: Human bone-marrow derived MSCs from young (n = 4, 21.8 years ± 2.4SD) and old (n = 4, 65.5 years ± 8.
3SD) donors were used to make chondrogenic, osteogenic and tenogenic tissue-engineered constructs. We utilised
an analytical method relying on extracted peptide intensities as a label-free approach for peptide quantitation by
liquid chromatography–mass spectrometry. Results were validated using western blotting.
Results: We identified proteins that were differentially expressed with ageing; 128 proteins in chondrogenic
constructs, 207 in tenogenic constructs and four in osteogenic constructs. Differentially regulated proteins were
subjected to bioinformatic analysis to ascertain their molecular functions and the signalling pathways. For all
construct types, age-affected proteins were involved in altered cell survival and death, and antioxidant and
cytoskeletal changes. Energy and protein metabolism were the principle pathways affected in tenogenic constructs,
whereas lipid metabolism was strongly affected in chondrogenic constructs and mitochondrial dysfunction in
osteogenic constructs.
Conclusions: Our results imply that further work on MSC-based therapeutics for the older population needs to
focus on oxidative stress protection. The differentially regulated proteome characterised by this study can
potentially guide translational research specifically aimed at effective clinical interventions.
Keywords: Mesenchymal stem cells, Chondrogenesis, Osteogenesis, Tenogenesis, Ageing, Label-free quantification,
Oxidative stress
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Background
Mesenchymal stem cells (MSCs) are a heterogeneous
population of multipotent cells with the ability to differ-
entiate into cells of mesenchymal origin to accommo-
date tissue homeostasis and repair. These cells have
prospective applications in clinical tissue regenerative
strategies, due to their potential to differentiate into
musculoskeletal cell lineages, including cartilage, bone
and tendon [1, 2], high ex-vivo expansion capacity and
relative ease of culture following isolation [3]. The prin-
ciples of tissue engineering involve a complex interplay
of factors and to what extent MSC phenotype and differ-
entiation capacity alter with ageing is unknown. Conse-
quently, any loss in functionality with age would have
profound consequences for the maintenance of tissue
viability and the quality of tissues. The capacity of MSCs
to differentiate into various types of tissue seems to
change with age [4, 5]. For example, MSCs in older age
are impaired with respect to osteogenic differentiation,
preferring the adipogenic pathway of differentiation [6].
However, many current research findings are conflicting.
For instance, relating to chondrogenic differentiation of
MSCs, one study identified a reduction in glycosamino-
glycan with age [7] whereas another found no change
[5]. Furthermore, in osteogenic differentiation one group
identified an increase in alkaline phosphatase with age
[8] whilst another demonstrated a decrease [9]. It is
thought these discrepancies could be due to the hetero-
geneous population which is propagated within and
amongst donor populations. One recent study demon-
strated that commercially isolated MSCs had a shorter
doubling time than freshly isolated cultures. This may be
due to commercially isolated cells having a more homo-
geneous population, eliminating uncertainty that hetero-
geneous freshly isolated populations enact on MSC
characterisation [10].
The regenerative capacity of MSCs is believed to be
due to their high proliferation and differentiation cap-
acities, paracrine action (such as the secretion of plas-
minogen activators and matrix metalloproteases;
important for extracellular matrix (ECM) remodelling),
and immunological privilege. However, therapeutic effect-
iveness of MSCs for most clinical applications remains
limited, possibly due to the attenuation of their regenera-
tive potential in aged patients with chronic diseases.
Nevertheless, MSCs have already been used in clinical tri-
als of cell therapy for cartilage repair and osteoarthritis
(reviewed in [11]), bone fracture healing [12] and in a lim-
ited number of tendon therapies [13, 14].
Because of the interest in MSCs for regenerative medi-
cine, and with an ever ageing population it is important
to understand how the sets of proteins in MSC-derived
musculoskeletal ‘tissue’ change with age, and what the
potential effects are on clinical outcome. In a recent re-
view, the basic protein inventory of a characteristic MSC
has been assembled which encompasses six functional
groups of proteins [15]. Further work has identified the
protein changes in osteogenic [16], myogenic [17], chon-
drogenic [18] and adipogenic differentiation [19] from
bone-marrow-derived MSCs (BM-MSCs).
Proteomics enables the set of proteins responsible for
a particular cell phenotype to be identified, as well as en-
abling insights into mechanisms responsible for age-
related alterations in musculoskeletal tissues [20]. Label-
free quantification proteomics methods are based on the
direct measurement of the mass spectrum (mass to
charge ratio of ions in the gas phase) acquired signal.
When constituent peptides are produced following pro-
tein digestion and are converted into ions, the most
abundant proteins will produce the most ions and thus
the greatest signal intensities [21]. This type of workflow
coupled with a high mass resolution mass spectrometer
and bioinformatics enables hundreds of proteins to be
identified and quantified in a single sample with high
specificity and sensitivity [22].
Little information is available concerning the cellular
and ECM protein changes that occur when BM-MSCs
from different biologically aged donors are differentiated
into chondrogenic or osteogenic constructs and no data
are available for tenogenic constructs. This is important
because tissue engineering aims to develop biomimetic
tissues that recapitulate biological, structural and
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functional characteristics of native tissue. Age-related
changes thus have potential implications for the tissue-
engineering strategies used for enhancing musculoskel-
etal repair. This study aims to evaluate and compare the
proteome of chondrogenic, osteogenic and tenogenic
constructs derived from young and old human BM-
MSCs in order to determine similar and distinct changes
in the construct proteome with ageing.
Methods
All chemicals are supplied by Sigma unless stated other-
wise. Human MSCs from young and old donors were pur-
chased from Stem Cell Technologies (Grenoble, France)
and Promocell (Heidelberg, Germany).
Cell culture and differentiation
Human bone-marrow-derived commercially available
MSCs from young (n = 4, 21.8 years ± 2.4SD) and old
(n = 4, 65.5 years ± 8.3SD) donors were grown to passage
4, and each donor was differentiated into chondrogenic,
osteogenic [16] and tenogenic [23] constructs as described
previously and used in all subsequent experiments [24].
Engineered tendon constructs were formed in six-well
plates coated with ~1.5 ml SYLGARD (WPI, Hertfordshire,
UK) and pinned with staples. For each construct, 0.4 ml of
0.6 × 106 cells/ml was suspended in 80 μl of 20 mg/ml fi-
brinogen to which 8 μl of 200 U/ml thrombin was added.
Then 160 μl of mixture was placed in each well to form
an even covering. Each cell-embedded fibrin gel was cul-
tured in 2 ml DMEM supplemented with 100 units/ml
penicillin/streptomycin, 10 % FBS, 500 ng/ml amphoteri-
cin, 2 mM L-glutamine, 200 μML-ascorbic acid 2-
phosphate, non-essential amino acid at 10 μl/ml concen-
tration and aprotinin at 10 μl/ml. Every other day the
edges of the constructs were scored using a fine pipette
tip and the media were changed. All constructs were fully
contracted between the staples and harvested at 28 days
post seeding [23]. All tissue culture was undertaken in 5 %
oxygen and media were changed every third day. MSCs
from each donor were analysed separately in the three lin-
eages and proteomic analysis was carried out on all prepa-
rations for each of eight donors.
Validation of differentiation
Differentiation was assessed for chrondrogenesis and
osteogenesis by comparison with control MSCs treated
identically except with maintenance media (complete
Dulbecco’s Modified Eagle’s Media; Gibco) using histology
and quantitative real-time PCR (qRT-PCR). Calcium de-
positions, a marker of bone formation and differentiation,
were determined in osteogenic constructs using Alizarin
red staining as described previously [25]. Chondrogenic
pellets were paraffin embedded and 4 μm sections taken
and further stained with Alcian Blue/Nuclear Fast Red.
Tendon constructs were fixed in 4 % paraformaldehyde,
longitudinally embedded in paraffin and 4 μm sectioned
on polylysine slides. Staining was undertaken with
Masson’s Trichrome (collagen) [26].
Transmission electron microscopy (TEM) of tendon
constructs was performed by fixation in 2.5 % glutaralde-
hyde in 0.1 M sodium cacodylate buffer for 8 hours,
followed by buffer washing procedure and second fixation
and contrast stain with 0.1 % osmium tetroxide for 90 -
minutes. Samples were stained with 8 % uranyl acetate in
0.69 % maleic acid for 90 minutes, dehydrated in ascend-
ing ethanol concentrations and embedded in epoxy resin.
Ultrathin cross-sections (60–90 nm) were cut with a
Reichert-Jung Ultracut on an ultramicrotome using a
diamond knife. Cut cross-sections were then mounted on
200 mesh copper grids and stained with ‘Reynold’s Lead
citrate’ stain for 4 minutes. Images were viewed in Philips
EM208S Transmission Electron Microscope at 80 k.
Total RNA was prepared from constructs using 0.5 ml
Tri Reagent (Ambion, Warrington, UK) per construct
with homogenisation using a fine needle and syringe.
The guanidinium thiocyanate–phenol–chloroform ex-
traction technique was used as described previously [27].
M-MLV reverse transcriptase and random hexamer oli-
gonucleotides were used to synthesise cDNA from RNA
(Promega, Southampton, UK) in a 25 ml reaction.
Aliquots of 1 ml were amplified by PCR in 20 ml reaction
volumes on an ABI 7300 Sequence Detector using a SYBR
Green PCR mastermix (Applied Biosystems, Warrington,
UK). cDNA was used for lineage-specific gene expression
markers using qRT-PCR relative to GAPDH [28]. Steady-
state transcript abundance of potential endogenous con-
trol genes was measured in the RNAseq data (unpublished
data). GAPDH was selected as the most stable endogenous
control gene. Primers used are presented in Additional
file 1: Table S1.
Protein extraction and sample preparation
Proteins were extracted from the constructs using either
guanidine hydrochloride as described previously [20]
(chondrogenic and osteogenic) or 0.1 % Rapigest™ [29]
(tenogenic), following optimisation of protein extraction
methods for each construct type (data not shown). Protein
extracts were normalised following protein assay using the
Bradford assay with Coomassie Plus™ protein assay reagent
(Thermo Scientific, Rockford, IL, USA) read at 660 nm. In-
solution trypsin digestion was undertaken on all samples as
described previously [20]. Samples were desalted using C18
tips (Merck Millipore, Watford, UK) [30].
One-dimensional SDS-PAGE
Construct soluble extracts of MSCs and constructs were
analysed by one-dimensional sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) to assess
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gross quantitative/qualitative differences in protein pro-
files [20]. Additionally, Rapigest™ extracts of mesenchy-
mal stems cells prior to differentiation were also
evaluated. Then 30 μg was loaded according to equal
volumes after ethanol precipitation and resolubilisation
in SDS loading buffer (Invitrogen) and stained with
Coomassie.
Mass spectrometry and label-free quantification
Liquid chromatography tandem mass spectrometry (LC-
MS/MS) was performed using a NanoAcquity™ ultraper-
formance LC (Waters, Manchester, UK) online to an
LTQ-Orbitrap Velos mass spectrometer (Thermo-Fisher
Scientific, Hemel Hempstead) as described previously
[21]. The proteomics data were deposited to the Proteo-
meXchange Consortium [31] via the PRIDE partner re-
pository with the dataset identifier PXD001952.
For label-free quantification the Thermo raw files of
the acquired spectra from in-solution tryptic digests
were analysed by the ProgenesisQI™ software (Version 1;
Waters, Manchester, UK) [21]. Briefly, the top five spec-
tra for each feature were exported from ProgenesisQI™
and utilised for peptide identification in PEAKS® 7 PTM
(Bioinformatics Solutions Inc., Ontario, Canada) using
the reviewed Uniprot human database. Search parame-
ters used were: 10 ppm peptide mass tolerance and
0.6 Da fragment mass tolerance; one missed cleavage
allowed; fixed modification, carbamidomethylation; and
variable modifications, methionine, proline, lysine oxida-
tion. Proteins were identified with a false discovery rate
(FDR) of 1 % and a minimum of two peptides per pro-
tein. The resulting peptide-spectrum matches were
imported into ProgenesisQI™ for label-free relative quan-
tification. Differentially expressed (DE) proteins were de-
fined with FDR p < 0.05 and ±2-fold regulation.
Neopeptide identification
For neopeptide determination of tenogenic constructs,
mass spectrometry data from the in-solution tryptic di-
gests were analysed. Neopeptides were identified by
searches against the reviewed Uniprot human database
using Mascot with search parameters as already stated
except: enzyme, semi-tryptic. Neopeptides were only in-
cluded if they passed a conservatively applied threshold
with e > 0.001. Patterns of fragmentation were deter-
mined for collagens, proteoglycans and glycoproteins.
Functional analysis of proteomics data
To determine gene ontology, functional analyses, net-
works, canonical pathways and protein–protein interac-
tions of age-related DE proteins in each construct type
we performed the analyses using the Protein ANalysis
THrough Evolutionary Relationships (PANTHER) Clas-
sification System [32], the functional analysis and
clustering tool from the Database for Annotation, Visu-
alisation, and Integrated Discovery (DAVID bioinformat-
ics resources 6.7) [33] and Ingenuity Pathway Analysis
(IPA) [34]. Proteins were further characterised and clas-
sified using MatrisomeDB [35].
Western blotting validation of mass spectrometry data
To confirm the mass spectrometry data, the relative
abundance of cartilage oligomeric matrix protein
(COMP) and biglycan in tenogenic and superoxide dis-
mutase 1 (SOD1) in the chrondrogenic protein extracts
was determined using automated western blotting (Wes
Simple Western Analysis; ProteinSimple, San Jose, CA,
USA) as described previously [36]. All reagents were
supplied by ProteinSimple. Simple western analysis was
performed according to the user manual. Protocols were
optimised for antibody and protein loading. In brief, pro-
tein extracts were mixed with a master mix to give a
final concentration of 0.004–0.2 mg/ml total protein, 1×
sample buffer, 1× fluorescent molecular weight markers
and 40 mM dithiothreitol. Samples were heated at 95 °C
for 5 min. Samples, blocking solution, primary anti-
bodies, horseradish peroxidase-conjugated secondary
antibodies, chemiluminescent substrate, and separation
and stacking matrices were loaded into designated wells
in a microplate. After plate loading, fully automated
electrophoresis and immunodetection took place with
the capillary system. Proteins were separated by molecu-
lar weight at 375 V for 25 minutes, and primary and sec-
ondary antibodies incubated for 30 minutes. All
antibodies were diluted in antibody diluent to the re-
quired concentrations (Additional file 2: Table S2).
Chemiluminescence was captured by a charge-coupled
device camera, and the digital image was analysed using
ProteinSimple Compass software. The relative amount
of each protein, relative to total protein content, was cal-
culated based on the peak area. A 29 kDa system control
antibody was spiked into each sample to provide within-
capillary normalisation. Statistical significance was deter-
mined using a Mann–Whitney test.
Statistical analysis
Statistical analysis was undertaken with Mann–Whitney
U tests for qRT-PCR and neopeptide analysis using
GraphPad Prism version 6.0 (GraphPad Software, San
Diego, CA, USA).
Results
Characterisation of tissue constructs
To confirm chondrogenic induction of MSCs, mature
markers of chondrocytes were assessed; Alcian Blue
staining for glycosaminoglycans and aggrecan, COL2A1
and SOX9 gene expression. In line with previous reports
[18] we identified an increase in Alcian Blue staining
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and aggrecan, COL2A1 and SOX9 expression [37]
(Fig. 1a–d), demonstrating chondrogenic differentiation of
MSCs. Osteogenic differentiation was evaluated with
Alizarin Red and RUNX2 gene expression. There was a
significant increase in staining with Alizarin Red both
visually and using quantitative analysis (Fig. 1e, f ) and in-
creased RUNX2 expression (Fig. 1g), demonstrating osteo-
genic differentiation of MSCs. Tenogenic differentiation
was evaluated histologically following Masson’s Trichrome
staining, indicating areas of organised and disorganised
collagen fibril formation within the constructs. This was
confirmed with TEM and with gene expression of
COL1A1 (Fig. 1 h, i). There was no qualitative difference
in the collagen organisation of tendon constructs derived
from young and old MSCs. Further genes previously
identified as markers of tendon expression [38] were
Fig. 1 Histochemical and gene expression analysis of chondrogenic, osteogenic and tenogenic lineage differentiation for MSCs. Images are
representative of all experiments. a MSC pellets cultured in control or chondrogenic media were fixed and stained with Alcian Blue (scale bar = 100 μm).
Gene expression of b aggrecan, c COL2A1 and d SOX9 following chondrogenic differentiation. Statistical evaluation was undertaken using
Mann–Whitney U test (n = 6). e Osteogenic differentiation from MSCs was confirmed with Alizarin Red S staining at day 21 to visualise
mineralised bone matrix following extraction of the calcified mineral from the stained monolayer at low pH. f Box and whisker plot showing
quantitative results of Alizarin red staining. Statistical significance, Mann–Whitney U test p < 0.001 (n = 12). g Gene expression of RUNX2
following osteogenesis. h Histology images of a tendon construct made from MSCs stained with Masson’s Trichrome to identify collagenous
matrix. Image was captured at ×4 magnification and ×10 magnification (inset, upper image) (scale bar = 100 μm). Example of more organised
areas of collagen is marked on the inset image (red). (Lower image) Ultrastructural analysis using scanning TEM. Presence of aligned extracellular
collagen fibrils (A) and less organised collagen (B) are inset (red) (scale bar = 1 μm). Tenogenic differentiation was also evaluated using gene
expression of i COL1A1, j SERPINF1 and k THBS4. For gene expression, data are represented as 2–ΔCT compared with GAPDH. Statistical evaluation
was undertaken using Mann–Whitney U test (n = 8) with data represented as 2–ΔCT compared with GAPDH. MSC mesenchymal stem cell
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significantly increased following tenogenic differentiation
but were not age related; serpin peptidase inhibitor F
(SERPINF1) (Fig. 1j) and thrombospondin 4 (THBS4)
(Fig. 1k).
SDS-PAGE comparative analysis of protein extracts
One-dimensional SDS-PAGE of the soluble protein ex-
tracts demonstrated differences in the intensity of the
staining and the number of bands between construct
type and MSCs but not with age. Osteogenic profiles
were most similar to undifferentiated MSCs, showing
more cellular profiles. The chondrogenic profiles were
the least complex, as demonstrated by few stained bands
(Fig. 2).
Protein identification
A total of 2226 proteins for chondrogenic constructs,
2233 proteins for osteogenic constructs and 615 proteins
for tenogenic constructs were identified within each
construct type. Additional file 3: Table S3 presents de-
tailed information on the identification of proteins in
each. Each dataset was subjected to gene ontology using
PANTHER which identified few differences in terms of
gene ontological terms between each construct type
(data not shown). Proteins in the ECM fraction were
classified and further investigated using MatrisomeDB
[35] (Additional file 3: Table S3). The overlap of proteins
shared between construct types is shown Additional file
4: Figure S1. The percentage of matrisomal proteins
compared with all proteins was 4 % for chondrogenic
and osteogenic constructs and 11 % for tenogenic
constructs.
Label-free relative quantification
To compare relative protein levels between young and
old chondrogenic, osteogenic and tenogenic constructs,
samples were processed for LC-MS/MS, and label-free
quantitative analysis undertaken using ProgenesisQI™.
Each young and old sample from each lineage was ana-
lysed separately and then comparisons were made be-
tween all young and old donors for each lineage.
Principal component analysis of all of the proteins iden-
tified revealed that the proteins clustered according to
the age of the donor with a principal component for
chondrogenic constructs of 71 %, osteogenic constructs
of 66 % and tenogenic constructs of 83 %. The number
Fig. 2 Coomassie-stained one-dimensional SDS-PAGE of the guanidine-soluble protein extracts of chrondrogenic and osteogenic constructs and
Rapigest™ extracts of tenogenic constructs compared with Rapigest™ extract of MSCs. Images are representative of all experiments. Equal protein
loading by weight (30 μg per well) allowed a qualitative and grossly quantitative comparison of soluble protein extracts. Vertical black line indicates
independent gels. Lines indicate digital splicing. MSC mesenchymal stem cell
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of DE proteins with at least a 2-fold change, p < 0.05 and
q < 0.05 was 128 in chondrogenic constructs (28 higher
in old, 100 lower), 207 in tenogenic constructs (201
higher in old, six lower) and four in osteogenic con-
structs (three higher in old – gamma-adducin (ADDG),
uveal autoantigen with coiled-coil domains and ankyrin
repeats (HOYNH8), and heterogeneous nuclear ribonu-
cleoprotein (ROA0) – one lower – aldehyde dehydro-
genase X(ALB1)) (Additional file 5: Table S4).
Gene ontology of DE proteins
Using DAVID analysis we identified ontology terms
which were shared and distinct between construct types.
For gene ontology analysis of the DE proteins for chon-
drogenic and tenogenic constructs we used the parame-
ters 2-fold change, p < 0.05 and q < 0.05. For osteogenic
analysis, because only four proteins were DE at 2-fold
change with p < 0.05 and q < 0.05, we investigated gene
ontology terms and undertook IPA analysis for the 63
DE proteins with 2-fold change and p < 0.05 (Additional
file 6: Table S5). A significant term common to all con-
structs was actin cytoskeleton organisation. For chon-
drogenic constructs DAVID terms were also principally
involved in tissue morphogenesis and cell adhesion, and
for tenogenic constructs these were principally glycolysis
and protein metabolism. For osteogenic constructs the
single significant term ‘ribonucleoproteins’ was identified
(Additional file 7: Table S6). A similar number of DE
matrisomal proteins was identified in chondrogenic and
tenogenic constructs but none in osteogenic constructs
(Additional file 3: Table S3). Four matrisomal proteins
were DE in both chondrogenic and tenogenic constructs
with age; COL4A2, matrix metalloproteinase 14
(MMP14), matrix remodelling associated 5 (MXRA5)
and thrombospondin 1(THBS1). In osteogenic con-
structs, four matrisomal proteins were DE: WNT1 indu-
cible signalling pathway protein 2 (WISP2), collagen
type XV alpha 1 (COL15A1), proline/arginine-rich end
leucine-rich repeat protein (PRELP) and serpin peptidase
inhibitor (SERPINE2) (Additional file 3: Table S3).
Proteins DE for chondrogenic and tenogenic constructs
(2-fold change, p < 0.05 and q < 0.05) and osteogenic
constructs (2-fold change and p < 0.05) were further
classified for gene ontology with PANTHER, demon-
strating both similarities and differences in the type of
proteins affected with age (Fig. 3).
Differential expressed genes and network analysis
For chondrogenic and tenogenic constructs the sets of
DE proteins associated with ageing were analysed with
Fig. 3 Pie charts depicting protein classification of DE proteins in ageing constructs using PANTHER. Proteins were demonstrated as DE when
quantified with ProgenesisQI™ with at least two unique peptides, a 2-fold change in expression and q < 0.05. First row, chondrogenic constructs;
second row, tenogenic constructs. a Biological processes, b molecular functions and c cellular components. Because osteogenic constructs had
only four DE proteins with the filters of a 2-fold change in expression. p < 0.05 and q < 0.05, PANTHER analysis was undertaken on DE proteins
quantified with ProgenesisQI™ with at least two unique peptides, a 2-fold change in expression and p < 0.05 (third row)
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IPA. The top canonical pathways, networks and diseases
and biological functions with ageing are presented in
Tables 1, 2 and 3 respectively. From the DE proteins as-
sociated with ageing input into IPA, a number of poten-
tial upstream regulators were identified in chondrogenic,
tenogenic and osteogenic constructs (Additional file 8:
Table S7). The activation z score is used to infer likely
activation states of upstream regulators based on com-
parison with a model that assigns random regulation di-
rections. Only upstream regulators with significant
activation z scores were investigated to increase confi-
dence in the data. Interesting upstream regulatory ana-
lysis revealed that targets of SMAD-2, SMAD-3, SMAD-
4 and transforming growth factor beta (TGFβ) are regu-
lated in chondrogenic constructs. Here TGFβ was pre-
dicted to be inhibited with ageing, with effects on tissue
development and chondrogenic differentiation. In con-
trast, TGFβ was identified in tenogenic constructs as an
activating upstream regulator in ageing. Targets of
hypoxia-induced factor-1 alpha (HIF1α) were activated
or inhibited in the same way as TGFβ in chondrogenic
and tenogenic constructs. Targets of epidermal growth
factor receptor family (ERBB4) were differentially regu-
lated in osteogenic constructs (Additional file 8: Table
S7). Interestingly, age-related changes in signalling path-
ways for chondrogenic constructs were principally in
lipid metabolism (Fig. 4a), for tenogenic constructs were
in glucose metabolism (Fig. 4b) and for osteogenic
constructs were in mitochondrial dysfunction (Fig. 4c).
Furthermore, age-related alterations in functions in
tenogenic constructs included protein metabolism
(Fig. 4d). Table 4 summarises the functional categories,
canonical pathways and networks identified from the
changes in protein expression in each construct with
ageing using IPA.
Validation of mass spectrometry results by automated
western blotting
Abundance of cartilage oligomeric matrix protein (COMP)
and biglycan (tenogenic) and superoxide dismutase 1
(SOD1) was validated by western blotting (Fig. 5). Appar-
ent molecular weights were larger than expected for
COMP and biglycan. This is probably due to samples not
being deglycosylated prior to western blotting, but this
may also be due to evident differences in molecular weight
(particularly for glycosylated proteins) using the Protein-
Simple system for the majority of antibodies due to a
difference in the separation matrix [39]. In agreement
with the mass spectrometry data, for tenogenic con-
structs COMP and biglycan were higher in abundance
(p = 0.05) in old constructs. SOD1 was higher in abun-
dance (p = 0.05) in the old chondrogenic constructs,
also supporting the mass spectrometry results.
Identification of ECM fragmentation patterns in tendon
constructs
Neopeptides were identified in all samples. Significantly
more neopeptides were identified in the tendon con-
structs derived from old MSCs than from young MSCs
(14 ± 2.5 versus 2.5 ± 1; p = 0.049). Together with
Table 1 Top canonical pathways from the IPA knowledge base that involve proteins differentially expressed in young compared
with old chondrogenic, tenogenic and osteogenic constructs
Construct Pathway p value Ratio
Chondrogenica LXR/RXR activation 6.01 × 10–7 8/121 (0.066)
FXR/RXR activation 8.69 × 10–7 8/127 (0.062)
Acute phase response signalling 7.36 × 10–6 8/169 (0.047)
Cholesterol biosynthesis I 5.49 × 10–5 3/13 (0.231)
Cholesterol biosynthesis II 5.49 × 10–5 3/13 (0.231)
Tenogenica Glycolysis I 5.15 × 10–9 7/25 (0.28)
Gluconeogenesis I 1.85 × 10–7 6/25 (0.24)
ILK signalling 6.45 × 10–7 12/186 (0.065)
Mitochondrial dysfunction 1.96 × 10–6 11/171 (0.064)
Protein ubiquitination pathway 3.10 × 10–6 13/255 (0.051)
Osteogenicb Mitochondrial dysfunction 1.29 × 10–4 5/171 (0.029)
Lipid antigen presentation by CD1 2.51 × 10–3 2/26 (0.077)
Integrin signalling 2.68 × 10–3 4/202 (0.02)
Oxidative phosphorylation 3.79 × 10–3 3/109 (0.028)
Glycerol-3-phosphate shuttle 8.58 × 10–3 1/3 (0.333)
aSignificant DE proteins with p < 0.05, q < 0.05 and ±2-fold change
bSignificant DE proteins with p < 0.05 and ±2-fold change
DE differentially expressed, IPA ingenuity pathway analysis
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significant pathways of 'activation of metabolism' and
'protein metabolism', this observation indicates increased
turnover in tendon constructs derived from older MSC
donors. A summary of the number of neopeptides iden-
tified in each condition is presented in Table 5. Very few
neopeptides were identified for non-collagenous proteins
whilst a large number of collagen proteins demonstrated
neopeptides.
Discussion
MSCs are an appealing source for cell-based treatment
of musculoskeletal diseases and injury. Ageing is associ-
ated with various altered cellular phenotypes. Further-
more, the regeneration potential of MSCs is reduced
with increasing age and is correlated with changes in
cellular functions [5, 24]. This study of chondrogenic,
osteogenic and tenogenic constructs derived from young
and old MSCs provides a comprehensive proteomic ana-
lysis of tissue constructs whilst concurrently enabling
improved understanding of the age-related functional
and biological variations, which may affect their applica-
tions to regenerative medicine. In addition, our approach
enables common and tissue-specific pathways of muscu-
loskeletal ageing in an in-vitro system to be identified.
Characterisation of the tissue constructs was under-
taken using standard methods following chondrogenic
and osteogenic differentiation. For tenogenic constructs
we used histological staining with Masson’s Trichrome
and TEM to ascertain the presence and organisation of a
collagenous matrix together with collagen type I, THBS4
[40] and SERPINEF1 gene expression. The latter two
have recently been identified as being the most DE genes
in tendon differentiation but with low expression in
chondrogenic differentiation [38]. There was heterogen-
eity in the response to differentiation of these markers
which was not age related, similar to that in aggrecan
expression in chondrogenic constructs. The conditions
of differentiation may impact on results. Because differ-
entiation involves culture with different factors, which
change according to the method used, it is conceivable
that there might an age-related change in response to al-
teration of these factors which could affect results. Fur-
ther work is required in this area.
The proteomic profiles of the constructs demonstrated
using 1D gels showed that there was no gross difference
in the profiles within construct type with ageing. When
these results were compared with the number of identi-
fied proteins there were a higher number of protein
identifications within the osteogenic (2233 proteins) and
chondrogenic (2226 proteins) constructs, indicating a
more complex proteome in these tissues. This was simi-
lar to the number of proteins identified in MSCs (2347
proteins) [24]. A Rapigest™-based protein extraction
workflow was utilised for tenogenic (615 proteins) con-
structs whereas a guanidine-based extraction was used
for chondrogenic and osteogenic constructs, because
Rapigest™ provided superior results compared with
guanidine for tenogenic constructs in terms of proteins
identified. The difference in number of protein identifi-
cations was probably due to the altered cell to ECM ra-
tios within constructs, evident from histological sections.
One limitation of the study is that it cannot be ruled out
Table 2 Top scoring networks from the IPA knowledge base that involve proteins differentially expressed in young compared with
old chondrogenic, tenogenic and osteogenic constructs
Construct Identification of associated network functions Score
Chondrogenica Cell death and survival, lipid metabolism, small molecule biochemistry 43
Cellular movement, cell death and survival, cancer 33
Connective tissue disorders, haematological disease, hereditary disorder 31
Cellular assembly and organisation, cellular development, connective tissue development and function 28
Cell signalling, nucleic acid metabolism, small molecule biochemistry 26
Tenogenica Carbohydrate metabolism, haematological disease, immunological disease 59
Developmental disorder, hereditary disorder, inflammatory disease 43
Cell-to-cell signalling and interaction, embryonic development, tissue development 36
Endocrine system development and function, energy production, small molecule biochemistry 36
Cellular assembly and organisation, cellular function and maintenance, cellular compromise 31
Osteogenicb Cellular assembly and organisation, tissue development, infectious disease 58
Cellular compromise, developmental disorder, haematological disease 32
Protein synthesis, developmental disorder, hereditary disorder 29
Lipid metabolism, nucleic acid metabolism, small molecule biochemistry 8
aSignificant DE proteins with p < 0.05, q < 0.05 and ±2-fold change
bSignificant DE proteins with p < 0.05 and ±2-fold change
DE differentially expressed, IPA ingenuity pathway analysis
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Table 3 Top diseases and biological functions from the IPA knowledge base that involve proteins differentially expressed in young
compared with old chondrogenic, tenogenic and osteogenic constructs classified as diseases and disorders, molecular and cellular
functions and physiological system development and function
Construct p-value No. molecules
Diseases and disorders
Chondrogenica Inflammatory Response 1.14E-03 - 1.05E-08 34
Developmental Disorder 7.11E-04 - 5.32E-08 33
Skeletal and Muscular Disorders 5.85E-04 - 5.32E-08 46
Cancer 1.21E-03 - 1.37E-07 112
Organismal Injury and Abnormalities 1.21E-03 - 1.37E-07 113
Tenogenica Cancer 1.26E-18 - 1.84E-03 173
Organismal Injury and Abnormalities 1.26E-18 - 1.96E-03 136
Reproductive System Disease 1.26E-18 - 1.84E-03 104
Immunological Disease 2.13E-12 - 5.18E-04 61
Respiratory Disease 2.78E-12 - 3.26E-04 48
Osteogenicb Infectious Disease 2.00E-05 - 1.54E-02 19
Developmental Disorder 4.83E-05 - 1.14E-02 8
Hereditary Disorder 4.83E-05 - 1.25E-02 11
Metabolic Disease 4.83E-05 - 1.14E-02 10
Neurological Disease 4.83E-05 - 1.77E-02 18
Molecular and cellular functions
Chondrogenica Cell Death and Survival 1.05E-03 - 2.51E-15 67
Cell Morphology 1.21E-03 - 7.47E-14 50
Cellular Movement 1.24E-03 - 8.51E-12 52
Cell-To-Cell Signalling and Interaction 1.21E-03 - 8.55E-12 45
Cellular Assembly and Organization 1.24E-03 - 8.63E-12 49
Tenogenica Cellular Movement 3.79E-20 - 2.14E-03 85
Cellular Growth and Proliferation 1.50E-18 - 1.91E-03 109
Cell Death and Survival 1.91E-15 - 2.04E-03 98
Cellular Assembly and Organization 1.62E-14 - 2.20E-03 85
Cellular Function and Maintenance 1.62E-14 - 2.20E-03 87
Osteogenicb Cell Morphology 2.33E-06 - 1.71E-02 19
Lipid Metabolism 2.42E-05 - 1.71E-02 6
Small Molecule Biochemistry 2.42E-05 - 1.72E-02 17
Molecular Transport 2.94E-05 - 1.71E-02 22
Protein Trafficking 2.94E-05 - 2.94E-02 5
Physiological system development and function
Chondrogenica Connective Tissue Development and Function 1.21E-03 - 2.75E-10 45
Tissue Development 1.24E-03 - 3.83E-09 60
Organismal Survival 1.18E-04 - 7.09E-09 47
Haematological System Development and Function 1.24E-03 - 1.05E-08 29
Immune Cell Trafficking 1.24E-03 - 1.05E-08 27
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Fig. 4 IPA generated networks derived from the proteins with different abundance in the chondrogenic, tenogenic and osteogenic constructs
derived from young and old MSCs. IPA identified that lipid metabolism signalling pathways were predominant in chondrogenic constructs (a). In
tenogenic constructs, signalling pathways were enriched for glucose metabolic processes (b). In osteogenic constructs, the principle signalling
pathway was mitochondrial dysfunction (c). One of the principle functions associated with the DE proteins in tenogenic constructs was also
protein metabolism (d). Green nodes, greater protein abundance in young; red nodes, greater protein abundance in old; white nodes, proteins not
differentially abundant between young and old. Intensity of colour is related to higher fold-change. Key to the main features in the networks
is shown
Table 3 Top diseases and biological functions from the IPA knowledge base that involve proteins differentially expressed in young
compared with old chondrogenic, tenogenic and osteogenic constructs classified as diseases and disorders, molecular and cellular
functions and physiological system development and function (Continued)
Tenogenica Tissue Development 1.98E-08 - 2.22E-03 79
Haematological System Development and Function 1.25E-07 - 1.47E-03 35
Immune Cell Trafficking 1.25E-07 - 1.47E-03 32
Cardiovascular System Development and Function 2.08E-07 - 2.11E-03 30
Skeletal and Muscular System Development and Function 3.87E-07 - 2.11E-03 47
Osteogenicb Nervous System Development and Function 2.33E-06 - 1.80E-02 12
Organ Morphology 7.75E-05 - 1.71E-02 15
Reproductive System Development and Function 7.75E-05 - 1.71E-02 7
Tissue Development 1.15E-04 - 1.71E-02 16
Cardiovascular System Development and Function 2.05E-04 - 1.59E-02 14
aSignificant DE proteins with p < 0.05, q < 0.05 and ±2-fold change
bSignificant DE proteins with p < 0.05 and ±2-fold change
DE differentially expressed, IPA ingenuity pathway analysis
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that some of the proteome pathway differences evident
could be due to the culture format or duration.
We used label-free quantification to identify age-related
DE proteins within each construct type. For our initial ana-
lysis we filtered data using p and q values (false-discovery
adjusted p values for multiple testing) in order to reduce
the number of false positives [41]. This produced 128 DE
proteins in chondrogenic constructs, 207 DE proteins in
tenogenic constructs but only four proteins for osteogenic
constructs. This indicates that at this level of filtering the
age of the MSC donor has little effect on the proteome of
osteogenic 2D constructs, whilst the protein composition
of tendon constructs is most affected by MSC donor age.
This disparity with the other two construct types could be
due to their differentiation in 3D. We used standard 3D
construct differentiation techniques for chondrogenic con-
structs due to problems with dedifferentiation into mono-
layers [42]. The pellet characteristics closely mimic cartilage
[43]. In tenogenic differentiation, uniaxial tension in 3D is a
requirement for differentiation [44]. For osteogenic con-
structs we used the standard 2D system because it is the
best described method and we could foresee problems with
the mass spectrometry compatibility of materials included
in many of the 3D osteogenic systems [45]. However, 2D
techniques inadequately produce the in-vivo environment
for stem cells established by extrinsic and intrinsic cell sig-
nalling affecting biological function and differentiation cap-
acity over time [46]. Therefore, the effect of MSC donor
age on the 3D osteogenic construct proteome should be
studied in future.
For the musculoskeletal constructs it is essential to dem-
onstrate the cellular phenotype and tissue composition,
especially the ECM molecules that play a structural role
and that contribute to the resulting mechanical properties.
Therefore we identified the compositional and age-related
DE matrisomal proteins in constructs. A number of matri-
somal proteins were shared between all constructs such as
COMP, TIMP1, decorin and biglycan, whilst some were
shared between some types such as TIMP3 between chon-
drogenic and tenogenic constructs. This demonstrates that,
similar to native tissues, the constructs have contrasting
ECM profiles [20, 47]. Furthermore, when DE matrisomal
proteins were investigated some proteins again shared age-
related changes (COL4A2, MXRA5, THBS1 and MMP14)
in chondrogenic and tenogenic constructs. Others such as
plasminogen in chondrogenic constructs, and lumican in
Fig. 5 Western blotting validations of mass spectrometry results.
COMP, biglycan and SOD1 abundance were confirmed by western
blotting. Representative western blots for tenogenic constructs
(a COMP and c biglycan) and chondrogenic constructs (e SOD1).
Abundance of each protein is expressed semi-quantitatively (b, d, f)
relative to total protein content. Statistical differences were assessed
with age in the respective construct and antibody analysis using
Mann–Whitney tests. Significant differences represented
with p≤ 0.05
Table 4 Summary of significant functional categories, canonical
pathways and networks identified from DE proteins by IPA in
constructs made from young or old MSCs for chondrogenic,
tenogenic and osteogenic constructs
Biological processes Chondrogenica Tenogenica Osteogenicb
Antioxidant changes ✓ ✓ ✓
Cell death and survival ✓ ✓ ✓
Cytoskeleton changes ✓ ✓ ✓
Energy metabolism x ✓ ✓
Protein metabolism x ✓ ✓
Lipid metabolism ✓ x ✓
Musculoskeletal
abnormalities increased
✓ ✓ x
Cell movement ✓ ✓ ✓
Cell proliferation ✓ ✓ ✓
Integrin signalling x ✓ ✓
aSignificant DE proteins with p < 0.05, q < 0.05 and ±2-fold change
bSignificant DE proteins with p < 0.05 and ±2-fold change
DE differentially expressed, IPA ingenuity pathway analysis, MSC mesenchymal
stem cell
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tenogenic constructs, were construct distinct. Interestingly,
in agreement with results from 1D gels, the tenogenic
constructs contained the most ECM matrisomal pro-
teins as a percentage of all proteins identified within
the construct type. Our findings revealed that the age
of the donor MSCs had distinct or similar effects on
construct ECM, depending on the differentiation
lineage. The consequence of these altered matrices on
the mechanical competence of the constructs requires
further work.
Gene ontology revealed that metabolic processes were
overrepresented in tenogenic constructs. This was also
evident using IPA, which identified an increase in glu-
cose and protein metabolism (both identified as acti-
vated in ageing), the latter related specifically to protein
expression, proteolysis, catabolism and anabolism. Pro-
tein metabolism was demonstrated, for example, by an
increase in abundance in old tendon constructs of
TIMP-1, TIMP-3, MMP-2 and MMP-14. Furthermore,
this was validated by neopeptide analysis, an indicator of
protein turnover [20, 30]. Neopeptides represent ECM
fragments produced by tissue remodelling. We have pre-
viously shown that neopeptide expression is altered in
normal tendon ageing and disease [20]. The changes
could be attributed to altered metabolism within the
cells present in ageing tendon constructs. However, the
increased abundance of proteases could also be due to
release of intracellular proteases because of cell death.
The DNA content of old tendon constructs was reduced
despite all constructs being seeded at an equivalent rate
at the start of the experiments. This could be due to cell
death in older constructs or reduced proliferation cap-
acity. However, because there was a concomitant in-
crease in DE ECM proteins, these protein metabolism
changes seem to be due to a dysregulation of protein
metabolism in ageing tendon constructs. These findings
may also help understand how the tendon undergoes
physiological remodelling that is evident in ageing.
Gene ontology also identified that DE age-related proteins
in chondrogenic constructs were higher for the cellular
component ECM and extracellular region proteins com-
pared with the other construct types, indicating that donor
age affects matrix proteins of chondrogenic constructs the
most. These age-related changes in the ECM could have
important implications for the quality of engineered tissue.
There were protein changes in lipid metabolism-
related proteins in chondrogenic constructs. In cartilage,
lipids are a source of energy and are incorporated into
structural components and signalling molecules. Chon-
drocytes express several proteins for fatty acid metabol-
ism and cholesterol biosynthesis and these molecules are
increased during chondrogenesis [48]. Chondrocyte lipid
peroxidation has been suggested to have a role in cartil-
age ageing [49]. We identified age-related changes in
proteins involved with LXR activation and cholesterol
biosynthesis. Given previous findings, it would seem that
MSC donor age has an impact on lipid metabolism
which could affect their chondrogenic potential further
given that our culture conditions were hypoxic.
A further interesting feature derived from pathway ana-
lysis was the demonstration of an age-related inflammatory
response in chondrogenic constructs, a significant feature
in chondrogenic constructs. Ageing MSCs are known to
undergo inflammageing and tissue-engineered cartilage
may be more predisposed compared with other tissue
types, similar to native ageing cartilage [50]. Because MSC-
derived chondrocytes are a potential treatment for chondral
lesions [11], the use of allogeneic MSCs from younger do-
nors may be beneficial in treating older patients. These
findings demonstrate that our use of young and old donor-
derived MSCs to produce musculoskeletal constructs could
be a useful model to study musculoskeletal ageing.
A principal age-related feature of osteogenic constructs
was mitochondrial dysfunction, when reactive oxygen
species (ROS)-mediated oxygen stress overpowers the
antioxidant defence system. Oxidative damage affects rep-
lication and transcription of mitochondrial DNA, leading
to a decline in mitochondrial function and enhanced ROS
production with further damage to mitochondrial DNA.
In all constructs we demonstrated age-related protein
changes involved in cell death and survival, and the alter-
ations in oxidative stress probably contribute to this. Our
results imply that MSC-derived tissue engineering from
older donors must focus on oxidative stress protection.
Pathway analysis revealed that actin cytoskeleton
changes were common to all ageing constructs. Others
have identified an age-affected alteration in cytoskeletal
organisation in rat MSCs [51]. In all ageing constructs,
similar to MSCs [24] we hypothesise that there is a de-
cline in responsiveness to mechanical and biological
Table 5 Number of neopeptides identified in each condition
for a range of collagens and glycoproteins
Mean number of neopeptides
Protein Young Old
COL1A2 0.0 1.0
COL2A1 0.0 1.0
COL5A1 0.0 1.3
COL6A1 2.0 2.3
COL6A2 0.0 1.0
COL6A3 0.0 2.8
COL8A1 1.5 1.3
COL12A1 1.0 4.0
Thrombospondin 1 2.0 3.3
Tenascin 1.0 1.8
Total 5.0 14.0
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signals due to a less dynamic cytoskeleton. The age-
related network of proteins involved in cell migration
and movement were also affected in all construct types.
In total these findings are consistent with altered cyto-
skeletal dynamics affecting cell movement through
coupling to actin organisation and turnover [52].
A number of upstream regulators of DE proteins were
identified in each construct type. Our analysis revealed a
number of significant transcriptional regulators potentially
responsible for the protein changes. These data provide a
starting point for future studies in MSC-derived tissue
engineering of musculoskeletal constructs from older
patients. One interesting finding was the contrasting roles
of TGFβ and HIF1α in the DE proteins from chondrogenic
and tenogenic constructs. TGFβ was significantly predicted
to affect protein changes relating to tissue development in
chondrogenic and tenogenic constructs and relating to dif-
ferentiation in chondrogenic constructs, but in opposite
directions; inhibited in chondrogenic but activated in teno-
genic. Whilst there is only indirect evidence for a role of
TGFβ in ageing, it is an important growth factor in devel-
opment and differentiation. In our study, TGFβ signalling
was predicted to be inhibited in chondrogenic constructs
and activated in tenogenic constructs. This could be due to
differing responses to oxidative stress previously identified
here or distinctive requirements for culture conditions
dependent on construct type. Furthermore, expression of
the sets of age and tissue-specific transcriptional regulators
may explain these findings, leading to similar molecular
scenarios for some pathways (antioxidant, cell survival and
cytoskeleton) but contrasting in others (e.g. protein and en-
ergy metabolism in tenogenic constructs and lipid metabol-
ism in chondrogenic constructs).
Finally, the functions of the DE proteins identified which
relate to cell death and survival, and antioxidant and
cytoskeletal changes, are associated and important for
chondrogenic, osteogenic and tenogenic differentiation.
Chondrogenesis is characterised by changes in cell shape
[42] and actin organisation is essential [53]. In tenogenesis,
cytoskeletal organisation is also paramount [54]. Further-
more, osteogenesis is tightly regulated by ROS (reviewed in
[55]). Age-related proteomic changes will thus affect the
ability and quality of tissue-engineered constructs.
The study of musculoskeletal ageing in bone, cartilage
and tendon is generally undertaken in isolation and it is
often difficult to attain aged matched tissue samples in
humans. We propose our approach as a model for muscu-
loskeletal ageing that could be probed further to identify
factors that may aid in recapitulation of a younger tissue
phenotype. This is because as musculoskeletal tissues age
they become more prone to age-related musculoskeletal
disease such as osteoarthritis, tendinopathy and osteopor-
osis. We have identified some shared age-related character-
istics (inflammageing, oxidative stress, cytoskeletal) which
raise the prospects that common therapeutic targets could
be developed to prevent these diseases. Understanding what
drives these changes in diverse tissues could lead to the
development of new therapeutic methods, which are advan-
tageous to the musculoskeletal system in general.
Conclusions
Mass spectrometry-based proteomics provides an efficient
method to monitor the complete profile of cellular and
ECM molecules from tissue-engineered constructs. The dif-
ferentially regulated proteome characterised by this study
can potentially guide translational research specifically
aimed at effective clinical interventions. Our data have pro-
vided valuable clues for our better understanding of the
underlying mechanisms that are responsible for age-related
changes in tissue-engineered constructs, thus assisting in
the application of MSCs in cell-based therapy for cartilage,
bone and tendon regeneration. These results also have sig-
nificant implications for therapeutic cell source decisions
(autologous or allogeneic), revealing the necessity of ap-
proaches to improve functionality of ageing MSCs.
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